Reducing early mortality in hemodialysis patients

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 6, 2008, Pages 595-599

  Hakim, Raymond M ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

Access; Catheter; Initiation of dialysis; Pre end stage renal disease education

Indexed keywords

BODY MASS; CATHETER INFECTION; COMORBIDITY; HEALTH CARE QUALITY; HEMODIALYSIS PATIENT; HUMAN; KAPLAN MEIER METHOD; KIDNEY FAILURE; MEDICARE; MORTALITY; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL WELL BEING; REVIEW; RISK FACTOR; SEPSIS; VASCULAR ACCESS;

COMORBIDITY; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF HEALTH CARE; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 56249100742     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283136746     Document Type: Review

References (12)

1. USRDS. Excerpts from United States Renal Data System: USRDS 1990 Annual Data Report; 1990. pp. 33-42.
2. Miskulin DC, Meyer KB, Martin AA, et al. Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis 2003; 41:149-161.
3. Miskulin DC, Martin AA, Brown R, et al. Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant 2004; 19:413-420.
4. Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident us hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2:89-99. This article is one of the larger studies of patients initiating dialysis and has one of the more interesting discussions about the divergent rates of mortality reported for patients initiating dialysis. It also highlights the impact of pre-ESRD care on those outcomes.
5. Soucie JM, McCllellan WM. Early death in dialysis patients: risk factors and impact on incidence and mortality rate. J Am Soc Nephrol 1996; 7:2169-2175.
6. Lorenzo V, Martin M, Rufino M, et al. Predialysis nephrologic care and a functioning arteriovenous fistula at entry are associated with better survival in incident hemodialysis patients: an observation cohort study. Am J Kidney Dis 2004; 43:999-1007.
7. Kazmi WH, Obrador GT, Khan SS, et al. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant 2004; 19:1808-1814.
8. Tseng C, Kern EFO, Miller DR, et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med 2008; 168:55-62. Prior nephrological care may also prolong dialysis-free survival in a large cohort of veteran patients with diabetes and kidney disease.
9. Van Manen JG, van Dijk PCW, Stel VS, et al. Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant 2007; 22:187-195. This study demonstrates that although a range of comorbidities influence mortality in these patients, they do not determine mortality.
10. Mauri JM, Cleries M, Vela E. Catalan Renal Registry. Design and validation of a model to predict early mortality in haemodialysis patients. Nephrol Dial Transplant 2008; 23:1690-1696. This study highlights the negative impact of malnutrition and catheters in the overall rate of mortality, in addition to the usual list of comorbidities; it also highlights the importance of functional autonomy as one of the predictors that are often not measured or reported.
11. Wingard RL, Pupim LB, Krishnan M, et al. Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. Clin J Am Soc Nephrol 2007; 2:1170-1175. This study describes a comprehensive program to address the needs of patients in the first 90 days of dialysis, which has resulted in a significant reduction in hospitalization and mortality up to 1 year of follow-up.
12. Johansen KL. Value of quality improvement reporting. Clin J Am Soc Nephrol 2007; 2:1104-1105. An editorial that compares the strength and limitation of quality improvement reporting and randomized clinical trials.